Volume 21, Issue 2 pp. 127-132
Original Article

Treatment Selection for Patients with Ductal Carcinoma In Situ (DCIS) of the Breast Using the University of Southern California/Van Nuys (USC/VNPI) Prognostic Index

Melvin J. Silverstein MD

Corresponding Author

Melvin J. Silverstein MD

Breast Service, Hoag Memorial Hospital Presbyterian, Newport Beach, California

Keck School of Medicine, University of Southern California, Los Angeles, California

Address correspondence and reprint requests to: Melvin J. Silverstein, MD, Gross Family Foundation Endowed Chair in Oncoplastic Surgery, Director, Hoag Breast Program, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA, or e-mail: [email protected]Search for more papers by this author
Michael D. Lagios MD

Michael D. Lagios MD

Breast Cancer Consultation Service, Tiburon, California

Search for more papers by this author
First published: 20 January 2015
Citations: 48

Abstract

The University of Southern California/Van Nuys Prognostic Index (USC/VNPI) is an algorithm that quantifies five measurable prognostic factors known to be important in predicting local recurrence in conservatively treated patients with ductal carcinoma in situ (DCIS) (tumor size, margin width, nuclear grade, age, and comedonecrosis). With five times as many patients since originally developed, sufficient numbers now exist for analysis by individual scores rather than groups of scores. To achieve a local recurrence rate of less than 20% at 12 years, these data support excision alone for all patients scoring 4, 5, or 6 and patients who score 7 but have margin widths ≥3 mm. Excision plus RT achieves the less than 20% local recurrence threshold at 12 years for patients who score 7 and have margins <3 mm, patients who score 8 and have margins ≥3 mm, and for patients who score 9 and have margins ≥5 mm. Mastectomy is required for patients who score 8 and have margins <3 mm, who score 9 and have margins <5 mm and for all patients who score 10, 11, or 12 to keep the local recurrence rate less than 20% at 12 years. DCIS is a highly favorable disease. There is no difference in mortality rate regardless of which treatment is chosen. The USC/VNPI is a numeric tool that can be used to aid the treatment decision-making process.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.